ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,064 | +32.5% | 11,367 | +26.3% | 0.01% | +50.0% |
| Q2 2023 | $803 | -11.9% | 9,000 | +5.9% | 0.00% | -20.0% |
| Q1 2023 | $911 | +5.1% | 8,500 | +19.7% | 0.01% | 0.0% |
| Q4 2022 | $867 | -99.9% | 7,100 | -26.0% | 0.01% | -28.6% |
| Q3 2022 | $991,000 | +11.1% | 9,600 | 0.0% | 0.01% | +16.7% |
| Q2 2022 | $892,000 | -21.6% | 9,600 | -1.0% | 0.01% | 0.0% |
| Q1 2022 | $1,138,000 | -12.8% | 9,700 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $1,305,000 | -22.8% | 9,700 | -8.5% | 0.01% | -33.3% |
| Q3 2021 | $1,690,000 | +38.2% | 10,600 | +14.0% | 0.01% | +50.0% |
| Q2 2021 | $1,223,000 | +2.0% | 9,300 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $1,199,000 | -30.2% | 9,300 | -9.7% | 0.01% | -30.0% |
| Q4 2020 | $1,718,000 | +27.9% | 10,300 | +18.4% | 0.01% | 0.0% |
| Q3 2020 | $1,343,000 | -47.8% | 8,700 | -50.0% | 0.01% | -9.1% |
| Q2 2020 | $2,574,000 | – | 17,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |